Evaluating DAPT in Pediatric Neurointervention

Pediatric neurointerventional procedures are becoming more common, yet management protocols often rely on adult data. Specifically, doctors use DAPT in pediatric neurointervention to reduce thromboembolic risks after stent or flow diverter placement. However, evidence regarding the safety and efficacy of these off-label regimens in children remains scarce. This retrospective study analyzed fifteen patients to assess clinical outcomes and complication rates.

The study cohort included patients aged 18 and under who received continuous dual antiplatelet therapy between 2016 and 2024. Most indications involved arterial aneurysms or venous sinus stenosis. Researchers noted that all participants received aspirin, combined typically with clopidogrel or ticagrelor. Consequently, the team tracked primary outcomes, focusing on thrombotic events like stroke and major bleeding complications.

Efficacy and Safety Findings

Notably, the results showed that no thromboembolic complications, strokes, or device thromboses occurred among the participants. This translates to an effective prevention rate within the study population. Regarding safety, only one patient experienced a significant retroperitoneal hemorrhage. This event was likely related to vascular access rather than the medication itself. Therefore, the findings suggest that DAPT is generally well-tolerated in pediatric patients.

Clinical Implications of DAPT in Pediatric Neurointervention

Although the sample size was small, the high efficacy suggests that adult-extrapolated protocols might be safe for children. Physicians must still exercise caution, as individual patient responses to clopidogrel can vary significantly. Furthermore, the medical community needs prospective studies to establish definitive guidelines for dosing and duration. Currently, DAPT provides a viable option for preventing serious complications after complex pediatric neurointerventional surgery.

Frequently Asked Questions

Is DAPT considered the standard of care for children?

While DAPT is the standard for adults, its use in children remains off-label. This study supports its effectiveness, but it is not yet officially standardized in pediatric guidelines.

What are the primary risks associated with DAPT in children?

The main risks include major bleeding complications, such as retroperitoneal hemorrhage. However, this study found a low incidence of such events directly attributable to the medication.

Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or a professional relationship. Always consult a qualified healthcare provider for diagnosis and treatment. Refer to the latest local and national guidelines for clinical practice.

References

Tumberger J et al. Dual antiplatelet therapy in pediatric neurointerventional procedures: a retrospective case series. J Neurosurg Pediatr. 2026 Apr 24. doi: 10.3171/2025.12.PEDS25558. PMID: 42030564.

Heiferman ML, et al. Antiplatelet therapy in pediatric neurointerventional surgery: a review of current evidence. Journal of NeuroInterventional Surgery. 2020.

Society of NeuroInterventional Surgery (SNIS). Antiplatelets and antithrombotics in neurointerventional procedures: Guideline update. 2023.